Monopar Therapeutics, Inc. (MNPR)
112.65
-1.73
(-1.51%)
USD |
NASDAQ |
Sep 09, 16:00
112.65
0.00 (0.00%)
After-Hours: 16:48
Monopar Therapeutics Enterprise Value : 633.55M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 633.55M |
| September 04, 2026 | 654.90M |
| September 03, 2026 | 661.54M |
| September 02, 2026 | 646.30M |
| September 01, 2026 | 654.96M |
| August 31, 2026 | 617.11M |
| August 28, 2026 | 616.84M |
| August 27, 2026 | 630.60M |
| August 26, 2026 | 629.12M |
| August 25, 2026 | 609.65M |
| August 24, 2026 | 613.28M |
| August 21, 2026 | 588.85M |
| August 20, 2026 | 610.06M |
| August 19, 2026 | 697.05M |
| August 18, 2026 | 664.90M |
| August 17, 2026 | 647.71M |
| August 14, 2026 | 624.56M |
| August 13, 2026 | 606.90M |
| August 12, 2026 | 637.04M |
| August 11, 2026 | 634.09M |
| August 10, 2026 | 646.77M |
| August 07, 2026 | 665.97M |
| August 06, 2026 | 672.68M |
| August 05, 2026 | 666.10M |
| August 04, 2026 | 660.94M |
| Date | Value |
|---|---|
| August 03, 2026 | 615.16M |
| July 31, 2026 | 593.08M |
| July 30, 2026 | 635.43M |
| July 29, 2026 | 586.87M |
| July 28, 2026 | 598.04M |
| July 27, 2026 | 606.37M |
| July 24, 2026 | 603.28M |
| July 23, 2026 | 575.29M |
| July 22, 2026 | 620.80M |
| July 21, 2026 | 628.11M |
| July 20, 2026 | 576.63M |
| July 17, 2026 | 611.67M |
| July 16, 2026 | 594.22M |
| July 15, 2026 | 595.36M |
| July 14, 2026 | 535.62M |
| July 13, 2026 | 559.38M |
| July 10, 2026 | 581.33M |
| July 09, 2026 | 567.23M |
| July 08, 2026 | 532.13M |
| July 07, 2026 | 504.94M |
| July 06, 2026 | 517.70M |
| July 02, 2026 | 522.19M |
| July 01, 2026 | 503.67M |
| June 30, 2026 | 487.29M |
| June 29, 2026 | 496.11M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 581.29M |
| Amgen, Inc. | 255.86B |
| Anika Therapeutics, Inc. | 268.42M |
| BioCryst Pharmaceuticals, Inc. | 2.798B |
| Imunon, Inc. | 8.166M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.313M |
| Total Expenses (Quarterly) | 5.313M |
| EPS Diluted (Quarterly) | -0.622 |
| Earnings Yield | -2.08% |
| Normalized Earnings Yield | -2.075 |